Bonus Biogroup LTD F-1 registration statements
The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.
YHD
Bonus Biogroup Ltd., a clinical-stage biotechnology company, is launching an initial public offering of 3,750,000 American Depositary Shares on Nasdaq to fund its advanced cell therapy and tissue engineering programs, despite recurring losses and substantial doubt about its ability to continue as a going concern.
YHD
Bonus Biogroup Ltd. is seeking to raise up to $17.25 million in a U.S. IPO on Nasdaq to fund clinical trials for its cell therapy and tissue engineering product candidates, BonoFill and MesenCure, despite significant recurring losses and substantial doubt about its ability to continue as a going concern.
YHD
Bonus BioGroup, a clinical-stage biotechnology company, files for an initial public offering in the U.S. to list its American Depositary Shares (ADSs) on the Nasdaq Capital Market, aiming to raise $20 million.